The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems

作者：Tingyi Li, Yanwei Chen, Shuai Li · 发表于：International Journal of Nanomedicine · 年份：2024 · DOI：10.2147/ijn.s480095 · 被引用次数：18 · 研究领域：Epigenetics and DNA Methylation、Genetics and Neurodevelopmental Disorders、Histone Deacetylase Inhibitors Research

Epigenetic dysregulation can significantly trigger the onset and progression of various diseases, epigenetic therapy is a new treatment strategy by changing DNA methylation, histone modification, N6-methyladenosine, chromatin modification and other epigenetic modifications to regulate gene expression levels for therapeutic purposes. However, small-molecule epigenetic drugs face challenges in disease treatment, such as lack of selectivity, limited therapeutic efficacy, and insufficient safety. Nanomedicine delivery systems offer significant advantages in addressing these issues by enhancing drug targeting, improving bioavailability, and reducing nonspecific distribution. This help minimize side effects while increasing both therapeutic effectiveness and safety of epigenetic drugs. In this review, we focus on the mechanism and role of epigenetic regulatory factors in diseases, as well as the challenges faced by small molecule inhibitors in treatment strategies, especially the research advancements in epigenetic drug delivery systems, review and discuss the therapeutic potential and challenges of using nanotechnology to develop epigenetic drug delivery systems.